Endo International | ENDP - Le Bénéfice D'Exploitation



Le Bénéfice D'Exploitation Changement Date
AbbVie USD 5.81B 1.23B 2025-12
Amarin USD -2.26M 564K 2025-12
ANI Pharmaceuticals USD 29.13M 6.3M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Hikma Pharmaceutical USD 348M 161M 2025-12
Ligand Pharmaceuticals USD 158.89M 149.17M 2025-09
Merck USD 6.24B 318M 2025-12
Novartis USD 4.06B 437M 2025-12
Pacira USD 3.19M 9.96M 2025-12
Perrigo USD 84.4M 9M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Phibro Animal Health USD 54.99M 2.36M 2025-12
Supernus Pharmaceuticals USD 13.82M 74.01M 2025-12
Takeda JPY 168.82B 479.89B 2025-12
Teva Pharmaceutical Industries USD 487M 581M 2025-12
Xeris Pharmaceuticals USD 16.77M 10.04M 2025-12
Zoetis USD 835M 101M 2025-12